Sarepta Therapeutics (SRPT) Misses Q1 EPS by 457c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
(Updated - May 2, 2023 5:18 PM EDT)
Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($5.86), $4.57 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $253.5 million versus the consensus estimate of $242.4 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- FDA approves Pfizer's Ibrance for HR+, HER2+ metastatic breast cancer
- GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
